Format

Send to

Choose Destination
FEBS Lett. 2000 Aug 4;478(3):205-8.

Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy mice.

Author information

1
Inserm U342, Hôpital Saint-Vincent de Paul, 82 avenue Denfert Rochereau, 75014, Paris, France. cartier@cochin.inserm.fr

Abstract

X-linked adrenoleukodystrophy (ALD) is a genetic demyelinating disorder characterized by accumulation of very long chain fatty acid (VLCFA) in tissues. Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, normalizes VLCFA in fibroblasts and plasma from ALD patients. We dietary treated ALD mice with simvastatin, an analog of lovastatin with similar pharmacokinetics and effects on plasma VLCFA in ALD patients at 20 or 60 mg/kg/day for 6-12 weeks. No decrease of VLCFA content was observed in mouse tissues, including the brain. A significant increase of VLCFA was rather observed in the brain of ALD mice at 60 mg/kg/day.

PMID:
10930569
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center